Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-36037
Titel: | COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated |
VerfasserIn: | Hüls, Anke Feany, Patrick T. Zisman, Sophia Isabella Costa, Alberto C. S. Dierssen, Mara Balogh, Robert Bargagna, Stefania Baumer, Nicole T. Brandão, Ana Claudia Carfi, Angelo Chicoine, Brian Allen Ghosh, Sujay Lakhanpaul, Monica Levin, Johannes Lunsky, Yona Manso, Coral Okun, Eitan Real de Asua, Diego Rebillat, Anne-Sophie Rohrer, Tilman R. Sgandurra, Giuseppina Valentini, Diletta Sherman, Stephanie L. Strydom, Andre on behalf of the Trisomy 21 Research Society COVID-19 Initiative |
Sprache: | Englisch |
Titel: | Vaccines |
Bandnummer: | 10 |
Heft: | 4 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | Trisomy 21 down syndrome COVID-19 SARS-CoV-2 BNT162b2 mRNA-1273 ChAdOx1 nCoV-19 Ad26.COV2.S vaccine hesitancy |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Individuals with Down syndrome (DS) are among the groups with the highest risk for severe COVID-19. Better understanding of the efficacy and risks of COVID-19 vaccines for individuals with DS may help improve uptake of vaccination. The T21RS COVID-19 Initiative launched an international survey to obtain information on safety and efficacy of COVID-19 vaccines for individuals with DS. De-identified survey data collected between March and December 2021 were analyzed. Of 2172 individuals with DS, 1973 (91%) had received at least one vaccine dose (57% BNT162b2), 107 (5%) were unvaccinated by choice, and 92 (4%) were unvaccinated for other reasons. Most participants had either no side effects (54%) or mild ones such as pain at the injection site (29%), fatigue (12%), and fever (7%). Severe side effects occurred in <0.5% of participants. About 1% of the vaccinated individuals with DS contracted COVID-19 after vaccination, and all recovered. Individuals with DS who were unvaccinated by choice were more likely to be younger, previously recovered from COVID-19, and also unvaccinated against other recommended vaccines. COVID-19 vaccines have been shown to be safe for individuals with DS and effective in terms of resulting in minimal breakthrough infections and milder disease outcomes among fully vaccinated individuals with DS. |
DOI der Erstveröffentlichung: | 10.3390/vaccines10040530 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-360372 hdl:20.500.11880/32948 http://dx.doi.org/10.22028/D291-36037 |
ISSN: | 2076-393X |
Datum des Eintrags: | 30-Mai-2022 |
Bezeichnung des in Beziehung stehenden Objekts: | Supplementary Material |
In Beziehung stehendes Objekt: | https://www.mdpi.com/2076-393X/10/4/530/s1?version=1648546734 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Pädiatrie |
Professur: | M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
vaccines-10-00530-v2.pdf | 1,18 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons